Tag Archives: biosimilar

New Guidance: Formal FDA Meetings for Biosimilar Product Development

On 01 April 2013, the FDA released its fourth guidance regarding the development of biosimilar products: Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants.  Biosimilars are biological products that are demonstrated to be “highly similar” or … Continue reading

Posted in FDA, Regulatory Strategy | Tagged , , | Comments Off on New Guidance: Formal FDA Meetings for Biosimilar Product Development

FDASIA, Part 4: Drug Supply Chain, Drug Shortages, and Other Provisions

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: … Continue reading

Posted in Clinical Trials, eCTD, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

FDASIA, Part 1: The “UFAs”

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part series, we will cover the major changes in FDASIA as follows: Part 1: The … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , , | 4 Comments

New Provisions in the FDA Safety and Innovation Act (aka PDUFA V)

On 09 July 2012, President Obama signed FDASIA (otherwise known as PDUFA V) into law. The reauthorization of PDUFA V has been working its way through both houses of Congress since May and has received uncharacteristically broad bipartisan and bicameral support. In 2007, PDUFA IV was hotly debated between the two chambers and was barely passed in time to replace the expiring PDUFA III, but this time, lawmakers were able to meet their goal of sending the President a reconciled bill well before the 30 September expiration date of PDUFA IV.

The new law will go into effect on 01 Oct 2012 and will sunset on 30 Sept 2017.

The FDASIA includes the following provisions Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , | 3 Comments

PDUFA V: A Funny Sounding Name for a Very Important Bill (Updated!)

Can you say PDUFA (pŭ-dōō-fŭ)?  The United States Senate can.  A very partisan Senate showed uncharacteristically bipartisan support for the Prescription Drug and User Fee Act (PDUFA) V, voting on 24 May 2012 to reauthorize PDUFA by a 96 to … Continue reading

Posted in FDA, Industry News | Tagged , , , , , , , , , , , , | 2 Comments